JOYZYME GROUP LIMITED
愉悅集團有限公司
（於開曼群島註冊成立的有限公司）
（股份代號：8622）

截至二零二六年六月三十日止六個月的中期業績公告

愉悅集團有限公司（「**本公司**」，及其附屬公司，「**本集團**」）董事（「**董事**」）會（「**董事會**」）欣然宣佈本集團截至二零二六年六月三十日止六個月的未經審核簡明綜合財務業績（「**二零二六年中期報告**」）連同二零二五年同期未經審核比較數字。本公告載列本集團二零二六年中期報告全文，並遵守香港聯合交易所有限公司GEM（「**GEM**」）證券上市規則（「**GEM上市規則**」）中有關中期業績初步公告隨附資料的相關規定。本公司二零二六年中期報告的印刷版本將適時寄發予本公司股東，並可於聯交所網站www.hkexnews.hk及本公司網站www.joyzymebiotech.com閱覽。

承董事會命
愉悅集團有限公司
聯席主席及執行董事
周訓勇博士

香港，二零二六年八月二十八日

於本公告日期，執行董事為張玉靜女士、周訓勇博士、張春光先生及潘禮賢先生；非執行董事為卜素博士；及獨立非執行董事為周國輝博士、王亞純女士及徐永得先生。

本公告的資料乃遵照《香港聯合交易所有限公司的GEM證券上市規則》而刊載，旨在提供有關本公司的資料；董事願就本公告的資料共同及個別地承擔全部責任。各董事在作出一切合理查詢後，確認就其所知及所信，本公告所載資料在各重要方面均屬準確完備，沒有誤導或欺詐成分，且並無遺漏任何事項，足以令致本公告或其所載任何陳述產生誤導。

本公告將自其刊發日期起計最少一連七日刊載於聯交所網站www.hkexnews.hk的「最新公司公告」內。本公告亦將刊載於本公司網站www.joyzymebiotech.com。

CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE")
香港聯合交易所有限公司(「聯交所」)GEM之特色

GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration.

Given that the companies listed on GEM are generally small and mid-sized companies, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board of the Stock Exchange and no assurance is given that there will be a liquid market in the securities traded on GEM.

Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this report ("**Report**"), make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of the Report.

This Report, for which the directors (the "**Directors**") of Joyzyme Group Limited (the "**Company**", and together with its subsidiaries, the "**Group**", "**we**" or "**our**") collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of the Stock Exchange (the "**GEM Listing Rules**") for the purpose of giving information with regard to the Group. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this Report is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this Report misleading.

GEM乃為較其他於聯交所上市之公司帶有較高投資風險之中小型公司提供一個上市之市場。有意投資者應了解投資於該等公司之潛在風險,並應經過審慎周詳考慮後方作出投資決定。

由於GEM上市公司通常為中小型公司,於GEM買賣之證券可能會較於主板買賣之證券承受較大之市場波動風險,及無法保證於GEM買賣之證券會有高流通市場。

香港交易及結算所有限公司及聯交所對本報告(「**本報告**」)的內容概不負責,對其準確性或完整性亦不發表任何聲明,並明確表示,概不對因本報告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。

本報告乃遵照聯交所GEM證券上市規則(「**GEM上市規則**」)之規定而提供有關愉悅集團有限公司(「**本公司**」,連同其附屬公司統稱「**本集團**」或「**我們**」)的資料,本公司董事(「**董事**」)願就本報告共同地及個別地承擔全部責任。董事經作出一切合理查詢後確認,就彼等所深知及確信,本報告所載資料在各重大方面均為準確及完整,且無誤導或欺詐成分及並無遺漏任何其他事項致使本報告或當中所載任何陳述產生誤導。

CONTENTS
目錄

CORPORATE INFORMATION
公司資料

Board of Directors
董事會

Executive Directors
執行董事

Dr. Zhou Xunyong *(Co-chairman)*
周訓勇博士*(聯席主席)*
Ms. Zhang Yujing *(Co-chairman)*
張玉靜女士*(聯席主席)*
Mr. Zhang Chunguang
張春光先生
Mr. Poon Lai Yin Michael
潘禮賢先生

Non-executive Directors
非執行董事

Dr. Bu Su
卜素博士
Dr. Xu Ming
(resigned on 30 March 2026)
徐明博士
(於二零二六年三月三十日辭任)

Independent Non-executive Directors
獨立非執行董事

Dr. Chow Kwok Fai Joseph
周國輝博士
Mr. Tsui Wing Tak
徐永得先生
Ms. Wang Yachun
王亞純女士

Audit Committee
審核委員會

Mr. Tsui Wing Tak *(Chairman)*
徐永得先生*(主席)*
Dr. Chow Kwok Fai Joseph
周國輝博士
Ms. Wang Yachun
王亞純女士

Remuneration Committee
薪酬委員會

Ms. Wang Yachun *(Chairman)*
王亞純女士*(主席)*
Dr. Chow Kwok Fai Joseph
周國輝博士
Mr. Zhang Chunguang
張春光先生

Nomination Committee
提名委員會

Ms. Zhang Yujing *(Chairman)*
張玉靜女士*(主席)*
Dr. Chow Kwok Fai Joseph
周國輝博士
Mr. Tsui Wing Tak
徐永得先生
Ms. Wang Yachun
王亞純女士

Company Secretary
公司秘書

Mr. Chau Lai Ki
周麗麒先生

Authorised Representatives (for the Purposes of the GEM Listing Rules)
授權代表(就GEM上市規則而言)

Ms. Zhang Yujing
張玉靜女士
Mr. Poon Lai Yin Michael
潘禮賢先生

Compliance Officer
合規主任

Mr. Poon Lai Yin Michael
潘禮賢先生

Legal Advisers as to Hong Kong Laws
有關香港法例的法律顧問

Howse Williams
何韋律師行

Auditor
核數師

Forvis Mazars CPA Limited
富睿瑪澤會計師事務所有限公司

CORPORATE INFORMATION
公司資料

Registered Office
註冊辦事處

Cricket Square
Hutchins Drive
P.O. Box 2681
Grand Cayman, KY1-1111
Cayman Islands

Principal Place of Business in Hong Kong
香港主要營業地點

Suite 1004, 10/F.
Chinachem Golden Plaza
77 Mody Road
No. 16 Science Museum Road
Kowloon
Hong Kong
香港
九龍
科學館道16號
麼地道77號
華懋廣場
10樓1004室

Principal Place of Business in the PRC
中國主要營業地點

1–3/F and 5/F, Building D
Shenzhen Junxuan
No. 16 Yinkui Road
Kui Xin Community
Kui Chong Office
Dapeng New District
Shenzhen
The PRC
中國
深圳市
大鵬新區
葵涌街道
葵新社區
銀葵路16號
深圳君軒
D棟一至三層及五層

Principal Share Registrar and Transfer Office in the Cayman Islands
開曼群島股份過戶登記處

Conyers Trust Company
(Cayman) Limited
Cricket Square
Hutchins Drive
P.O. Box 2681
Grand Cayman, KY1-1111
Cayman Islands

Hong Kong Share Registrar and Transfer Branch Office
香港股份過戶登記分處

Tricor Investor Services Limited
17/F., Far East Finance Centre
16 Harcourt Road
Hong Kong
卓佳證券登記有限公司
香港
夏慤道16號
遠東金融中心17樓

Company's Website
公司網址

http://www.joyzymebiotech.com

Stock Code
股份代號

8622

MANAGEMENT DISCUSSION AND ANALYSIS
管理層討論及分析

BUSINESS REVIEW

Biological Reagents and Auxiliary Reproductive Supplies and Equipment Segment

The Group continued to focus on the research, production, and sales of male fertility in-vitro diagnostic ("**IVD**") reagents in the People's Republic of China (the "**PRC**"). The product portfolio increased to 35 biological reagents, including 32 male fertility IVD reagents, 2 parasite antibody detection reagents, and 1 Epstein-Barr virus antibody detection reagent.

Revenue from this segment reached approximately RMB13.0 million for the six months ended 30 June 2026 (the "**Reporting Period**"), an approximately 5.4% increase compared to the six months ended 30 June 2025 (the "**Corresponding Period**"). Sales of core male fertility IVD reagents slightly grew by approximately 4.4% to approximately RMB10.4 million, accounting for approximately 79.8% of the segment's total revenue. Sales of auxiliary reproductive supplies and equipment rose by approximately 47.0% to approximately RMB1.0 million, reflecting sustained market demand.

During the Reporting Period, the Group had an improvement of Sperm Morphology Analysis Assay Kit and completed its Class II medical device registration, further strengthened its fertility diagnostics portfolio. These reagents will be launched to the market in the second half of the year.

業務回顧

生物製劑及輔助生育用品和設備分部

本集團繼續深耕中國男性不育體外診斷試劑的研究、生產及銷售。產品組合增加至35種生物製劑，包括32種男性不育體外診斷試劑、2種寄生蟲系列檢測試劑及1種EB病毒檢測試劑。

於截至二零二六年六月三十日止六個月(「**報告期間**」)，該分部收入約達人民幣13.0百萬元，較截至二零二五年六月三十日止六個月(「**去年同期**」)增長約5.4%。核心產品男性不育體外診斷試劑銷售額同比增長約4.4%至約人民幣10.4百萬元，佔分部總收入約79.8%。輔助生育用品及設備銷售增長約47.0%至約人民幣1.0百萬元，反映市場需求的持續韌性。

於報告期間，本集團改進精子形態分析檢測試劑盒及完成其第二類醫療器械註冊，進一步強化其不育診斷產品組合。此等試劑將於下半年推出市場。

Healthcare Products and Supplements Segment

The Group completed the acquisition of equity interests in Hunan Keyue Biotechnology Company Limited (“**Keyue**”) (the “**Acquisition**”) in June 2025 to expand its women’s health market presence. Keyue’s results were consolidated into the Group’s financial statements, contributing approximately RMB3.5 million to revenue in the Reporting Period.

The Group recommenced operations of its Nutronic brand in early 2026 to diversify its brand portfolio and capture growing demand for health-related products from ageing consumers. Supported by 27 valid Natural Health Product licences from Health Canada, a mature overseas supply chain and global business network, the Group is strategically well-positioned to extend its market presence across the health-product segment. Nutronic recorded revenue of approximately RMB115,000 for the Reporting Period.

健康產品及保健品分部

本集團於2025年6月完成收購湖南可悅生物科技有限公司(「**可悅**」)的股權(「**收購事項**」)，以擴展於女性健康市場之佈局。可悅之業績已合併計入本集團財務報表，於報告期內貢獻收益約人民幣3.5百萬元。

本集團於二零二六年年初重啟Nutronic品牌之營運，以多元化本集團品牌組合，並把握老年消費者對健康相關產品日益增長之需求。憑藉加拿大衛生部頒發的27項有效天然保健產品牌照、成熟的海外供應鏈及全球業務網絡，本集團於健康產品領域具備戰略優勢，可有效拓展市場版圖。Nutronic於報告期內錄得收益約人民幣115,000元。

FUTURE PROSPECTS

Looking ahead to the remainder of 2026, the Group holds a cautiously optimistic outlook amid a global macro-environment of muted consumer demand, geopolitical complexities and moderate projected growth of Gross Domestic Product (“**GDP**”) in the PRC. Responding to heightened health awareness among mature consumers and growing demand for personalised healthcare, the Group will execute a multi-dimensional growth strategy shifting from traditional product supply to an integrated healthcare-service ecosystem. It will scale up its healthcare products and supplements segment and pursue overseas geographic expansion to capture cross-border opportunities.

未來前景

展望二零二六年餘下時間，面對全球宏觀環境中消費需求疲弱、地緣政治局勢複雜及中國內地國內生產總值預期溫和增長之局面，本集團持審慎樂觀態度。因應成熟消費者健康意識持續提升，以及個人化醫療保健需求日益增長，本集團將推行多維度增長策略，由傳統產品供應轉型為綜合醫療保健服務生態系統。本集團將擴大保健產品及補充品業務規模，同時積極拓展海外市場版圖，以把握跨境業務機遇。

Supported by its global footprint and agile research and development framework, the Group will continue investing in product development and exploring sales channels across North America, Southeast Asia and the PRC. Expansion plans will be carefully tailored to each jurisdiction's regulatory, cultural and competitive conditions. Leveraging North American scientific expertise and PRC-based supply-chain efficiencies, the Group will enhance e-commerce capabilities and diversify wholesale businesses to build a resilient sales network less reliant on any single market.

憑藉本集團之全球佈局及靈活研發框架，本集團將持續投入產品開發，並積極探索北美、東南亞及中國等地之銷售渠道。各項拓展計劃將因應各地監管法規、文化習俗及競爭態勢而審慎制定。本集團將結合北美之科研專長與中國內地之供應鏈效率優勢，強化電子商務營運能力，並推動批發業務多元化，以構建具韌性之銷售網絡，減少對任一單一市場之依賴。

As it pursues new growth avenues, the Group will consolidate the technical foundations of its existing operations. It will further develop chemiluminescence technology with sperm mitochondrial diagnostic reagent and anti-Mullerian hormone, for assessing male fertility and reproductive potential. These measures provide a robust operational base for the Group's strategic diversification in 2026 and beyond.

於開拓新增長方向之際，本集團亦將鞏固現有業務之技術基礎，進一步發展化學發光技術的應用，配合精子線粒體診斷試劑及抗穆勒氏管荷爾蒙，評核男性不育及生殖潛力。此等措施為本集團於二零二六年及未來之戰略多元化提供穩固之營運基礎。

FINANCIAL REVIEW

Revenue

The Group's revenue increased by approximately RMB4.3 million, or approximately 34.3%, from approximately RMB12.3 million for the Corresponding Period to approximately RMB16.6 million for the Reporting Period. The increase in revenue was mainly due to the acquisition of Keyue, which brought approximately RMB3.5 million of revenue from sales of healthcare products and supplements for the Reporting Period.

財務回顧

收益

於報告期間，本集團錄得的收益較去年同期的約人民幣12.3百萬元增加約人民幣4.3百萬元或約34.3%至約人民幣16.6百萬元。收益增加主要由於收購可悅，於報告期間帶來銷售健康產品及保健品分部的收益約人民幣3.5百萬元。

Sales of male fertility IVD reagents products remained to be our major products which accounted for approximately 79.8% of our total revenue generated from our sales of biological reagents and auxiliary reproductive supplies and equipment segment for the Reporting Period. Revenue from sales of male fertility IVD reagents products for the Reporting Period was approximately RMB10.4 million, which represented an increase of approximately RMB438,000 or approximately 4.4% from approximately RMB9.9 million for the Corresponding Period.

男性不育體外診斷試劑產品仍為我們的主要產品，其於報告期間之銷售額佔本集團生物製劑及輔助生育用品和設備分部總收益約79.8%。銷售男性不育體外診斷試劑產品於報告期間之收益約為人民幣10.4百萬元，較去年同期的約人民幣9.9百萬元增加約人民幣438,000元或約4.4%。

Gross Profit and Gross Profit Margin

The Group recorded a gross profit of approximately RMB10.6 million for the Reporting Period, representing an increase of approximately RMB2.2 million, or approximately 25.5%, from approximately RMB8.4 million for the Corresponding Period.

The Group's gross profit margin decreased from approximately 68.3% for the Corresponding Period to approximately 63.8% for the Reporting Period, which mainly was due to lower margin for healthcare products and supplements segment.

毛利及毛利率

本集團於報告期間錄得毛利約人民幣10.6百萬元，較去年同期之約人民幣8.4百萬元增加約人民幣2.2百萬元或約25.5%。

本集團的毛利率由去年同期約68.3%減少至於報告期間約63.8%，其主要由於健康產品及保健品分部的毛利率較低。

Other Income and Other Losses

Other income decreased approximately RMB110,000 or approximately 47.6% from approximately RMB231,000 for the Corresponding Period to approximately RMB121,000 for the Reporting Period. The significant decrease was primarily attributable to less interest income from bank and loan.

We recorded other losses of approximately RMB289,000 for the Reporting Period, compared to other gains of approximately RMB147,000 for the Corresponding Period. Such change was mainly attributable to the fluctuations in foreign exchange rate between foreign currency and RMB, the majority of which was unrealised foreign exchange difference.

其他收入及其他虧損

其他收入由去年同期約人民幣231,000元減少約人民幣110,000元或約47.6%至於報告期間約人民幣121,000元。該大幅減少乃主要歸因於來自銀行及貸款利息收入減少。

我們於報告期間錄得其他虧損約人民幣289,000元，相對我們於去年同期其他收益約人民幣147,000元。有關轉變主要由於外幣與人民幣的匯率波動，其中大部分為未變現匯兌差異。

Impairment Losses

The Group recorded a decrease in impairment losses on trade receivables (net of reversals) of approximately RMB250,000 for the Reporting Period, from RMB381,000 for the Corresponding Period.

Additionally, the Group recorded a reversal of impairment losses on loan and loan interest receivables and refundable consideration paid of approximately RMB113,000 for the Corresponding Period. No provision or reversal of impairment loss recorded for the same category for the Reporting Period. Such reversal mainly reflects the repayments of the loan receivables for the Corresponding Period.

減值虧損

本集團錄得貿易應收款項減值虧損（扣除撥回），由去年同期為約人民幣381,000元減少至報告期間約人民幣250,000元。

此外，本集團於去年同期錄得應收貸款及貸款利息和可收回已支付對價減值虧損回撥約人民幣113,000元，而報告期間並無計提或回撥同類別的減值準備。該回撥主要是於去年同期應收貸款償還所致。

Expenses

Selling and distribution expenses increased by approximately RMB547,000 or approximately 15.5%, from approximately RMB3.5 million for the Corresponding Period to approximately RMB4.1 million for the Reporting Period. The increase was primarily attributable to the consolidation of the financial result of Keyue and the increased spending on the healthcare product and supplement segment during the Reporting Period.

Administrative expenses increased from approximately RMB5.2 million for the Corresponding Period to approximately RMB6.0 million for the Reporting Period, which represented an increase of approximately RMB801,000 or approximately 15.5%. The increase was mainly attributable to the consolidation of the financial result of Keyue during the Reporting Period.

Research and development expenses increased from approximately RMB1.8 million for the Corresponding Period to approximately RMB2.3 million for the Reporting Period, which represented an increase of approximately RMB449,000 or approximately 24.4%. The increase was mainly attributable to the clinical research conducted by the Group for quality control of seminal plasma biochemical products.

開支

銷售及分銷開支由去年同期約人民幣3.5百萬元增加約人民幣547,000元或約15.5%至於報告期間約人民幣4.1百萬元。該增加主要由於報告期間綜合可悅財務結果，及對健康產品及保健品分部的投入增大。

行政開支由去年同期約人民幣5.2百萬元增加約人民幣801,000元或約15.5%至於報告期間約人民幣6.0百萬元。該增加乃主要由於報告期間綜合可悅財務結果。

研發開支由去年同期約人民幣1.8百萬元增加約人民幣449,000元或約24.4%至於報告期間約人民幣2.3百萬元。該增加主要由於本集團就精漿生化產品質量控制進行臨床研究工作。

During the Reporting Period, finance costs significantly increased to approximately RMB244,000 from approximately RMB68,000 for the Corresponding Period. It was mainly attributable to the significant increase in interests on unsecured borrowing and interests on lease liabilities under application of Hong Kong Financial Reporting Standard ("**HKFRS**") 16.

於報告期間，融資成本大幅增加至約人民幣244,000元，由去年同期約人民幣68,000元。主要歸因於大幅增加無抵押貸款利息及應用香港財務報告準則(「**香港財務報告準則**」)第16號後租賃負債的利息。

Results for the Period

期內業績

The loss for the period was approximately RMB2.4 million for the Reporting Period as compared to approximately RMB2.4 million for the Corresponding Period.

於報告期間，期內虧損為約人民幣2.4百萬元，而去年同期則為約人民幣2.4百萬元。

Basic loss per share for the Reporting Period was RMB0.47 cent, as compared to RMB0.47 cent for the Corresponding Period.

於報告期間每股基本虧損為人民幣0.47分，而去年同期則為人民幣0.47分。

Taxation

稅項

The PRC enterprise income tax rate applicable to the Group's subsidiaries in the PRC ranged from 5% to 15% (during the Corresponding Period: 15%), whereas no assessable profit arising from Hong Kong during the Reporting Period (during the Corresponding Period: Nil).

本集團附屬公司適用之中國企業所得稅率為介乎5%至15%(去年同期：15%)，而報告期間並無在香港產生應課稅溢利(去年同期：無)。

SHARE OPTION SCHEME

購股權計劃

The Company has adopted the Share Option Scheme pursuant to an ordinary resolution passed by the shareholders in the extraordinary general meeting on 13 January 2020 (the "**Share Option Scheme**"). The Share Option Scheme is a long-term incentive scheme of the Company to reward its employees, Directors and other eligible participants for their contributions to the Group and to assist the Group in its recruitment and retention of high calibre employees and other eligible participants who are instrumental to the growth and development of the Group.

本公司已根據股東於二零二零年一月十三日的股東特別大會上通過的一項普通決議案採納購股權計劃(「**購股權計劃**」)。購股權計劃乃本公司的長期激勵計劃，旨在獎勵其僱員、董事及其他合資格參與者對本集團作出貢獻，同時協助本集團招聘及挽留高素質僱員及其他對本集團成長及發展至關重要的合資格參與者。

On 9 April 2020, the Company announced the granting of an aggregate of 26,008,000 share options, subject to the acceptance by the grantees, at an exercise price of HK$0.125 per share of the Company to the eligible persons under the Share Option Scheme. The market price of the Company's shares at the date of grant was HK$0.125 per share. All of the share options are exercisable from the date of acceptance by a grantee to 8 April 2030 (both days inclusive). Each of the grantees has paid HK$1 to the Company on acceptance of the offer of share option. Details are set out in the Company's announcement dated 9 April 2020.

於二零二零年四月九日，本公司公佈根據購股權計劃向合資格人士授出合共26,008,000份購股權，惟受限於承受人接納，行使價為每股本公司股份0.125港元。於授出日期，本公司股份的市價為每股股份0.125港元。全部購股權可由承接人接納日至二零三零年四月八日行使(包括首尾兩日)。各承授人已於接納購股權要約時向本公司支付1港元。有關詳情載於本公司日期為二零二零年四月九日的公告。

As at 1 January 2026 and 30 June 2026, all share options granted was either exercised or cancelled.

於二零二六年一月一日及二零二六年六月三十日，所有已授出購股權均已獲行使或已注銷。

As at 1 January 2025 and 30 June 2025, the number of shares in respect of which options had been granted and remained outstanding was 19,504,000.

於二零二五年一月一日及二零二五年六月三十日，已授出且尚未行使之購股權所涉及之股份數目為19,504,000股。

No share options had been granted, exercised or forfeited during the Reporting Period and the Corresponding period.

於報告期間及去年同期，概無購股權授出、行使或沒收。

All the existing share options of the Company are vested upon granting.

本公司之所有現有購股權乃於授出時歸屬。

The fair values of share options determined at the date of grant using the Binomial Option Pricing Model was at HK$0.1125 per option, with the following key inputs:

於授出日期使用二項式購股權定價模式釐定之購股權之公平值為每份購股權0.1125港元，且關鍵輸入數據如下：

The following assumptions were used to calculate the fair values of share options:

計算購股權之公平值時已使用以下假設：

Closing share price immediately before date of grant	HK$0.123
Grant date share price	HK$0.125
Exercise price	HK$0.125
Expected life	10 years
Expected volatility	103.1%
Dividend yield	Nil
Risk-free interest rate	0.778%

緊接授出日期之前的收市股價	0.123港元
授出日期之股價	0.125港元
行使價	0.125港元
預期年期	十年
預期波幅	103.1%
股息率	無
無風險利率	0.778%

The binomial model has been used to estimate the fair value of the share options. The value of the share options is subject to the limitations of the binomial model and a number of assumptions which are subjective and difficult to ascertain. Changes in the subjective input assumptions could materially affect the fair value estimate.

二項式模式乃用於估計購股權之公平值。購股權之價值受限於二項式模式的限制及多項假設，相關假設屬主觀因素且難以確定。主觀輸入值假設如有變動會對公平值估值造成重大影響。

LIQUIDITY, FINANCIAL RESOURCES AND CAPITAL STRUCTURE

流動資金、財務資源及資本架構

Our Group funded the liquidity and capital requirements primarily through internally generated funds from operating activities, equity financing and debt financing.

本集團主要透過經營活動所產生的內部資金、股權融資及債務融資，為流動資金及資本需求提供資金。

As at 30 June 2026, our Group recorded total cash and bank balances and bank deposit with maturity over three months of approximately RMB39.2 million compared to approximately RMB41.9 million as at 31 December 2025, which were mainly placed with major banks in the PRC and denominated in RMB and United States Dollars ("**US$**"). The decrease was mainly due to the payments of daily operating expenses.

於二零二六年六月三十日，本集團錄得現金及銀行結餘及存款日起三個月以上到期之銀行存款總額約為人民幣39.2百萬元，而於二零二五年十二月三十一日，本集團之現金及銀行結餘總額約為人民幣41.9百萬元，分別主要存放於中國主要銀行，並分別以人民幣及美元（「**美元**」）計值。該減少乃主要由於日常營運開支付款。

For the Reporting Period, the Group entered into 2 loan agreements with a controlling shareholder in the amount of HK$2 million and HK$3 million respectively. The loans are unsecured, fixed interest rate of 3% per annum and repayable on demand (31 December 2025: Nil).

於報告期間，本集團與一家控股股東簽訂2份貸款協議，金額分別為港幣2百萬元及港幣3百萬元。該等貸款為無抵押、固定年利率為3%，並須按要求償還（二零二五年十二月三十一日：無）。

As at 30 June 2026, the interest-bearing borrowings, interest-bearing borrowing from a controlling shareholder and the lease liabilities under application of HKFRS 16 were approximately of approximate RMB2.3 million, RMB1.8 million and RMB1.3 million respectively (31 December 2025: approximately of RMB3.6 million, Nil and RMB1.4 million, respectively). The gearing ratio of our Group calculated based on the unsecured interest-bearing borrowings and the lease liabilities divided by total equity as at 30 June 2026 was approximately 15.6% (31 December 2025: approximately 9.7%).

於二零二六年六月三十日，計息貸款、自一名控股股東的計息借款及應用香港財務報告準則第16號後的租賃負債分別約人民幣2.3百萬元、人民幣1.8百萬元及人民幣1.3百萬元（二零二五年十二月三十一日：分別約人民幣3.6百萬元、無及人民幣1.4百萬元）。於二零二六年六月三十日，本集團的資本負債比率（按無抵押計息借款及租賃負債除以權益總額計算）約為15.6%（二零二五年十二月三十一日：約9.7%）。

Details of the movement in the Company's share capital are set out in note 19 in the Notes to the unaudited condensed consolidated financial statements. The capital structure of the Group comprised of issued share capital, reserves and non-controlling interests. Total equity amounted to approximately RMB49.1 million as at 30 June 2026 (31 December 2025: approximately RMB51.2 million).

本公司股本變動之詳情載於未經審核簡明綜合財務報表附註19。本集團的資本架構包括已發行股本、儲備及非控股權益。權益總額於二零二六年六月三十日約為人民幣49.1百萬元（二零二五年十二月三十一日：約人民幣51.2百萬元）。

EMPLOYEES AND REMUNERATION POLICIES

The emolument policy for the employee of the Group is set up by the management on the basis of their merit, qualifications and competence. Under the emolument policy, the basis of determining the emolument payable to Directors is subject to the decision of the remuneration committee of the Company. As at 30 June 2026, the Group had 98 full-time employees (31 December 2025: 101) located in Hong Kong and the PRC for operation. Details of the staff costs, including Directors' remuneration, incurred by the Group are set out in note 7 in the Notes to the unaudited condensed consolidated financial statements in this Report.

僱員及薪酬政策

本集團僱員的薪酬政策乃管理層根據彼等之特長、資格及能力設立。根據薪酬政策，應付董事之酬金須由本公司薪酬委員會釐定。於二零二六年六月三十日，本集團於香港及中國擁有98名全職僱員（二零二五年十二月三十一日：101名）開展業務。有關本集團所產生員工成本（包括董事酬金）之詳情，載於本報告未經審核簡明綜合財務報表附註之附註7。

The remuneration committee will review and determine the remuneration and compensation packages of the Directors after having considered their responsibilities, workload, time devoted to our Group and the performance of our Group.

薪酬委員會將考慮董事各自的職責、工作量、為本集團貢獻的時間及本集團的業績表現檢討後釐定董事之薪酬及報酬包。

PRINCIPAL RISKS AND UNCERTAINTIES

The Group believed that there were certain risks and uncertainties involved in the operations, some of which were beyond the Group's control. A detailed discussion of the risk factors was set forth in the section headed "Risk Factors" in our prospectus dated 30 November 2018.

主要風險及不明朗因素

本集團認為營運涉及若干風險及不明朗因素，其中有一部分乃本集團無法控制。有關風險因素的詳細討論載於日期為二零一八年十一月三十日之招股章程「風險因素」一節。

FOREIGN EXCHANGE EXPOSURE

The functional currencies of our operations, assets and liabilities were mostly denominated in RMB. Therefore, we were not exposed to any significant foreign exchange risk for realised losses, except for our HK$, US$ and CAD$ denominated bank balances. The Group currently did not have a foreign currency hedging policy. The Group did not engage in any derivatives agreements and did not commit to any financial instruments to hedge its foreign exchange exposure throughout the Reporting Period. The management will closely monitor our Group's foreign currency exposure and will consider hedging significant foreign currency exposure should the need arises.

外匯風險

我們營運、資產及負債的功能貨幣大部分以人民幣計值。因此，除我們的港元、美元及加元計值銀行結餘外，我們並無面臨任何變現損失的重大外匯風險。本集團現時並無外匯對沖政策。本集團並無參與任何衍生工具協議，且並無承諾任何金融工具以對沖其於報告期間的外匯風險。管理層將密切監控本集團的外匯風險，並將於有需要時考慮對沖重大的外幣風險。

TREASURY POLICIES

The Group will continue to employ a prudent treasury policy in managing the Group's cash balances and maintain strong and healthy liquidity to ensure that the Group is well placed to take advantage of future growth opportunities.

庫務政策

本集團將繼續採用審慎的庫務政策管理本集團的現金結餘，並維持穩健的流動資金，以確保本集團作好準備把握日後的增長機遇。

MATERIAL ACQUISITIONS AND DISPOSALS OF SUBSIDIARIES AND AFFILIATED COMPANIES

The Group did not make any material acquisitions and disposals of subsidiaries and affiliated companies.

重大收購及出售附屬公司及關聯公司

本集團並無作出任何重大收購及出售附屬公司及關聯公司。

SIGNIFICANT INVESTMENT HELD

As at 30 June 2026, the Group did not have any significant investment held.

重大投資持有

於二零二六年六月三十日，本集團並無持有任何重大投資。

PLEDGE OF ASSETS

As at 30 June 2026, the Group did not pledge any assets of its material for lease liabilities (31 December 2025: Nil).

資產抵押

於二零二六年六月三十日，本集團並沒有抵押任何重大資產（二零二五年十二月三十一日：無）。

CAPITAL COMMITMENTS

As at 30 June 2026 and 31 December 2025, the Group did not have any capital commitments in respect of the acquisition of property, plant and equipment.

資本承擔

於二零二六年六月三十日和二零二五年十二月三十一日，本集團就購買物業、廠房及設備，沒有任何資本承擔。

CONTINGENT LIABILITIES

As at 30 June 2026, the Company had no outstanding corporate guarantee (31 December 2025: Nil). As at 30 June 2026, the Group had no banking facilities and did not have any significant contingent liabilities (31 December 2025: Nil).

或然負債

於二零二六年六月三十日，本公司概無尚未償還公司擔保（二零二五年十二月三十一日：無）。於二零二六年六月三十日，本集團概無銀行融資及並無任何重大或然負債（二零二五年十二月三十一日：無）。

FUTURE PLANS FOR MATERIAL INVESTMENTS OR CAPITAL ASSETS

Save as disclosed elsewhere in the Report, the Group does not have other plans for material investments and capital assets as at the date of this Report.

有關重大投資或資本資產的日後計劃

除本報告其他部分所披露者外，本集團於本報告日並無其他有關重大投資及資本資產的計劃。

DIVIDEND

The Directors do not recommend the payment of any dividend for the six months ended 30 June 2026 (six months ended 30 June 2025: Nil).

SUBSEQUENT EVENTS

Save as disclosed elsewhere in the Report, since 30 June 2026 up to the date of this Report no significant events affecting the Company have taken place.

CHANGE OF COMPANY NAME

On 19 January 2026, following the passing of the special resolution in relation to the change of name of the Company at an extraordinary general meeting, the Certificate of Incorporation on Change of Name of the Company was issued by the Registry of Companies in the Cayman Island certifying that the change of name of the Company from "Huakang Biomedical Holdings Company Limited" to "Joyzyme Group Limited" and the adoption of dual foreign name in Chinese from "華康生物醫學控股有限公司" to "愉悅集團有限公司" has become effective. The certificate of registration of alteration of name of registered non-Hong Kong company was issued by the Registrar of Companies in Hong Kong on 30 January 2026 confirming the alteration of the Company's name from "Huakang Biomedical Holdings Company Limited 華康生物醫學控股有限公司" and the registration of the Company's new name of "Joyzyme Group Limited 愉悅集團有限公司" in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong). Details are set out in the announcements of the Company dated 15 December 2025, 22 December 2025, 23 December 2025, 15 January 2026 and 4 February 2026.

股息

董事不建議派付截至二零二六年六月三十日止六個月的任何股息(截至二零二五年六月三十日止六個月：無)。

期後事項

除於本報告其他部分所披露者外，自二零二六年六月三十日直至本報告日並無發生影響本公司的重大事件。

更改公司名稱

於二零二六年一月十九日，在股東特別大會上通過有關更改本公司名稱的特別決議案後，開曼群島公司註冊處發出公司更改名稱註冊證書，證明本公司名稱由「Huakang Biomedical Holdings Company Limited」更改為「Joyzyme Group Limited」，而中文雙重外文名稱由「華康生物醫學控股有限公司」更改為「愉悅集團有限公司」一事已告生效。香港公司註冊處處長於二零二六年一月三十日發出註冊非香港公司變更名稱註冊證明書，確認本公司名稱由「Huakang Biomedical Holdings Company Limited華康生物醫學控股有限公司」更改，且本公司新名稱「Joyzyme Group Limited愉悅集團有限公司」已根據香港法例第622章公司條例第16部於香港註冊登記。詳情載於本公司日期為二零二五年十二月十五日、二零二五年十二月二十二日、二零二五年十二月二十三日、二零二六年一月十五日及二零二六年二月四日的公告。

OTHER INFORMATION
其他資料

DIRECTORS' AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY OR ANY ASSOCIATED CORPORATION

董事及最高行政人員於本公司或任何相聯法團之股份、相關股份及債權證的權益及淡倉

As at 30 June 2026, the interests and short positions of the Directors and chief executive of the Company in the Shares, underlying Shares and debentures of the Company or any of the associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "**SFO**")) which, once the Shares are listed on GEM of the Stock Exchange, will have to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including any interest or short positions which they are taken or deemed to have under such provision of the SFO) or will be required, pursuant to section 352 of the SFO, to be entered in the register referred to therein, or will be required, pursuant to the Rules 5.46 to 5.67 of the GEM Listing Rules relating to securities transactions by the Directors, to be notified to the Company and the Stock Exchange pursuant to the Model Code for Securities Transactions by directors of listed issuers, will be as follows:

於二零二六年六月三十日，董事及本公司最高行政人員於本公司或其任何相聯法團(定義見香港法例第571章證券及期貨條例(「**證券及期貨條例**」)第XV部)的股份、相關股份及債權證中，擁有(一旦股份於聯交所GEM上市後)須根據證券及期貨條例第XV部第7及8分部知會本公司及聯交所的權益及淡倉(包括根據證券及期貨條例有關條文彼等被當作或視為擁有的任何權益或淡倉)，或根據證券及期貨條例第352條須登記於該條所指的登記冊內的權益及淡倉，或根據有關董事進行證券交易的GEM上市規則第5.46至5.67條上市發行人董事進行證券交易之標準守則須知會本公司及聯交所的權益及淡倉如下：

Long Positions in the Shares

於股份之好倉

Ordinary shares of HK$0.01 each of the Company

本公司每股面值0.01港元之普通股

Name of Directors/ Chief Executive 董事／最高行政人員姓名	Capacity/ Nature of Interest 身份／權益性質	Number of ordinary shares held[1] 所持普通股數目[1]	Percentage of shareholding[2] 股權百分比[2]
Dr. Zhou Xunyong 周訓勇博士	Interests of controlled corporation[3] 受控法團權益[3]	259,520,000	50.35%
Mr. Zhang Chunguang 張春光先生	Beneficial owner 實益擁有人	3,976,000	0.8%
Mr. Poon Lai Yin Michael 潘禮賢先生	Beneficial owner 實益擁有人	4,000,000	0.8%

Notes:

(1) All interest stated are long positions.

(2) The calculation is based on the total number of 515,472,000 Shares in issue as at 30 June 2026.

(3) Anselme Limited ("**Anselme**") is beneficially owned as to 100% by Dr. Zhou Xunyong, who is deemed to be interested in all the Shares held by Anselme for the purpose of SFO.

附註：

(1) 所有所列權益均為好倉。

(2) 此乃基於二零二六年六月三十日的已發行股份總數515,472,000股計算。

(3) Anselme Limited(「**Anselme**」)由周訓勇博士實益擁100%權益，根據證券及期貨條例，其被視為於Anselme為所持有的所有股份中擁有權益。

Long Position in the Ordinary Shares of Associated Corporations

於相聯法團普通股之好倉

Name of Directors/ Chief Executive 董事／最高行政人員姓名	Name of Associated Corporation 相聯法團名稱	Capacity/ Nature of Interest 身份／權益性質	Number of ordinary shares held (Note) 所持普通股數目 (附註)	Percentage of shareholding 股權百分比
Dr. Zhou Xunyong 周訓勇博士	Anselme	Beneficial owner 實益擁有人	1 share of US$1.00 each 1股每股1.00美元之股份	100%

Note: All interest stated are long positions.

附註： 所有所列權益均為好倉。

Save as disclosed above, as at 30 June 2026, none of the Directors and the chief executive of the Company had any interests or short positions in the Shares, underlying Shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which would have to be notified to the Company and the Stock Exchange under Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which he is taken or deemed to have under such provision of the SFO) or which would be required, pursuant to Section 352 of the SFO, to be entered in the register referred to therein, or which would be required pursuant to Part XV of the SFO or Rules 5.46 to 5.67 of the GEM Listing Rules to be notified to the Company and the Stock Exchange.

除上文所披露者外，於二零二六年六月三十日，概無董事及本公司最高行政人員於本公司或其任何相聯法團(定義見證券及期貨條例第XV部)的股份、相關股份或債權證中擁有根據證券及期貨條例第XV部第7及第8分部須知會本公司及聯交所的任何權益或淡倉(包括根據證券及期貨條例有關條文彼被當作或視為擁有之權益或淡倉)，或根據證券及期貨條例第352條須登記於該條所述登記冊的任何權益或淡倉，或根據證券及期貨條例第XV部或GEM上市規則第5.46條至第5.67條須知會本公司及聯交所的任何權益或淡倉。

SUBSTANTIAL SHAREHOLDERS' AND OTHERS PERSONS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

As at 30 June 2026, so far as is known to the Directors, the following persons (not being a Director or chief executive of the Company) had interest or short position in the Shares or underlying Shares which fell to be disclosed to the Company and the Stock Exchange under Divisions 2 and 3 of Part XV of the SFO or as recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO:

主要股東及其他人士於股份及相關股份之權益及淡倉

於二零二六年六月三十日，據董事所知，以下人士(既非董事亦非本公司最高行政人員)於股份或相關股份中擁有根據證券及期貨條例第XV部第2及第3分部須向本公司及聯交所披露，或記錄於本公司根據證券及期貨條例第336條須存置之登記冊內的權益或淡倉：

Name of Shareholders 股東名稱	Capacity/ Nature of Interest 身份／權益性質	Number of ordinary shares held[(1)] 所持普通股數目[(1)]	Percentage of shareholding[(2)] 股權百分比[(2)]
Anselme	Beneficial owner[(3)] 實益擁有人[(3)]	259,520,000	50.35%

Notes:

(1) All interests stated are long positions.

(2) The calculation is based on the total number of 515,472,000 Shares in issue as at 30 June 2026.

(3) Anselme is beneficially owned as to 100% by Dr. Zhou Xunyong, who is deemed to be interested in all the Shares held by Anselme for the purpose of SFO.

附註：

(1) 所有所列權益均為好倉。

(2) 此乃基於二零二六年六月三十日的已發行股份總數515,472,000股計算。

(3) Anselme由周訓勇博士實益擁有100%權益，其根據證券及期貨條例被視為於Anselme為所持有股份中擁有權益。

DIRECTORS' INTEREST IN CONTRACTS

Save as otherwise disclosed in this Report, no transactions, arrangements and contracts of significance in relation to the Group's business to which the Company, or any of its holding company or subsidiaries was a party and in which a Director of the Company and their respective connected parties had a material interest, whether directly or indirectly, subsisted at any time for Reporting Period.

董事於合約的權益

除本報告另有披露者外，於報告期間內的任何時間，本公司或其任何控股公司或附屬公司概無參與訂立與本集團業務有關，而本公司董事及彼等各自關連人士於當中直接或間接擁有重大權益的重大交易、安排及合約。

DIRECTORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

Save as otherwise disclosed in this Report, at no time during the Reporting Period and up to the date of this Report, have the Directors and the chief executive of the Company and their respective close associates (as defined in the GEM Listing Rules) had any interests in, or had been granted, or exercised any rights to acquire benefits by means of the acquisition of shares in, or debentures of, the Company and/or its associated corporations (within the meaning of SFO).

董事收購股份或債權證的權利

除本報告另有披露者外，於報告期間的任何時間及直至本報告日期，董事及本公司最高行政人員及彼等各自之緊密聯繫人(定義見GEM上市規則)概無於本公司及╱或其相聯法團(定義見證券及期貨條例)之股份或債權證中擁有任何權益或獲授予或行使可藉收購本公司及╱或其相聯法團股份或債權證而獲取利益之任何權利。

COMPETING INTERESTS

The Directors confirm that none of the substantial shareholders or the Directors and their respective close associates (as defined in the GEM Listing Rules) is interested in any business apart from the business operated by our Group which competes or is like to compete, directly or indirectly, with our Group's business as required to be disclosed pursuant to Rule 11.04 of GEM Listing Rules during the Reporting Period and up to the date of this Report.

競爭權益

董事確認，於報告期間及直至本報告日期，概無主要股東或董事或彼等各自之緊密聯繫人(定義見GEM上市規則)，根據GEM上市規則第11.04條要求披露於本集團經營業務以外且直接或間接與本集團業務構成競爭或可能構成競爭的任何業務中擁有權益。

PURCHASE, SALES OR REDEMPTION OF LISTED SECURITIES

There were no purchases, sales or redemptions of the Company's listed securities by the Company or any of its subsidiaries during the Reporting Period.

購買、出售或贖回上市證券

於報告期間，本公司或其任何附屬公司概無購買、出售或贖回本公司任何上市證券。

CHANGES IN DIRECTORS INFORMATION

Except for Dr. Zhou Xunyong resigned as a director of DT Cloud Star Acquisition Corporation (stock code: DTSQ.NASDAQ) and Linkage Global Inc (stock code: LGCB.NASDAQ) in April 2026, the shares of the both companies are listed on the Nasdaq Stock Market, there is no change in information of the Directors required to be disclosed pursuant to Rule 17.50A(1) of the GEM Listing Rules.

董事資料變更

除周訓勇博士於二零二六年四月離任DT Cloud Star Acquisition Corporation(股份代號:DTSQ.NASDAQ)及Linkage Global Inc(股份代號：LGCB.NASDAQ)董事，上述兩家公司的股份均於納斯達克證券市場上市，概無須根據GEM上市規則第17.50A(1)條予以披露之董事資料變動。

CORPORATE GOVERNANCE PRACTICES

The Board of the Directors (the "**Board**") is committed to achieving high corporate governance standards.

The Board believes that good corporate governance standards are essential in providing a framework for the Company to safeguard the interests of shareholders, enhance corporate value, formulate its business strategies and policies, and enhance its transparency and accountability.

The Company has applied the principles and code provisions as set out in the Corporate Governance Code (the "**CG Code**") contained in Appendix C1 of the GEM Listing Rules.

The Company adopted and complied with, where applicable, the CG Code during the Reporting Period and up to the date of this Report (the "**Relevant Period**").

The Board will continue to monitor and review the Company's corporate governance practices to ensure compliance with the CG Code.

The Board conducted reviews of the system of internal controls of the Group to ensure that an effective and adequate internal control system is in place. The Board also convened meetings to discuss financial, operational and risk management control.

MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted a code of conduct regarding securities transactions by the Directors on terms no less exacting than the required standard of dealings concerning securities transactions by the Directors as set out in Rules 5.48 to 5.67 of the GEM Listing Rules (the "**Model Code**") as its own code governing securities transactions of the Directors (the "**Required Standard**"). Having made specific enquiry of all the Directors, all of them confirm that they have fully complied with the Required Standard during the Relevant Period.

企業管治常規

董事會(「**董事會**」)致力於持守較高的企業管治標準。

董事會相信，良好的企業管治標準對為本公司提供框架以保障股東利益、提升企業價值、制定業務策略及政策，以及提高透明度及問責性是必不可少的。

本公司已應用GEM上市規則附錄C1所載企業管治守則(「**企業管治守則**」)載列的原則及守則條文。

本公司自報告期間及直至本報告日期止期間(「**有關期間**」)已採納及遵守(如適用)企業管治守則。

董事會將持續監察及檢討本公司的企業管治常規，以確保遵守企業管治守則。

董事會已檢討本集團的內部監控系統，以確保建立有效及充分的內部監控系統。董事會亦召開會議討論財務、營運及風險管理監控。

進行證券交易的標準守則

本公司已採納一套有關董事進行證券交易的操守守則作為其本身監管董事證券交易的守則(「**必守標準**」)，其條款嚴格程度並不遜於GEM上市規則第5.48至5.67條所載有關董事進行證券交易的必守標準(「**標準守則**」)。經向全體董事作出特定查詢後，全體董事均已確認彼等於有關期間內已遵守必守標準。

Pursuant to Rule 5.66 of the Model Code, the Directors have also requested any employee of the Company or director or employee of a subsidiary of the Company (the "**relevant employees**") who, because of his office or employment in the Company or a subsidiary, is likely to possess inside information in relation to the securities of the Company, not to deal in securities of the Company when he would be prohibited from dealing by the Model Code as if he were a Director. No incident of non-compliance of the Required Standard by the relevant employees was noted by the Company.

根據標準守則第5.66條，董事亦已要求本公司的任何僱員、或本公司附屬公司的任何董事或僱員(「**有關僱員**」)，不得利用彼等因在本公司或附屬公司的職務或工作而可能管有與本公司證券有關的內幕消息，在標準守則禁止董事買賣證券之期間買賣本公司的證券。本公司並無獲悉有關僱員違反必守標準的事件。

AUDIT COMMITTEE AND REVIEW OF INTERIM RESULTS

The audit committee of the Company has been established with its terms of reference in compliance with Rules 5.28 to 5.33 of the GEM Listing Rules, and code provisions D.3.3 and D.3.7 of the CG Code ("**Audit Committee**"). The Audit Committee consists of three independent non-executive Directors, namely Mr. Tsui Wing Tak (Chairman), Dr. Chow Kwok Fai Joseph and Ms. Wang Yachun.

The main duties of the Audit Committee are to assist the Board in reviewing the financial information and reporting process, risk management and internal control systems, effectiveness of the internal audit function, scope of audit and appointment of external auditors, and arrangements to enable employees of the Company to raise concerns about possible improprieties in financial reporting, internal control or other matters of the Company.

The financial information in this Report has not been reviewed nor audited by the Company's auditor, but the Audit Committee has reviewed the unaudited condensed consolidated financial results of the Group for the Reporting Period and is of the opinion that the preparation of such statements complied with the applicable accounting standards, the requirements under the GEM Listing Rules and other applicable legal requirements, and that adequate disclosures have been made.

審核委員會及審閱中期業績

本公司審核委員會已告成立，並遵照GEM上市規則第5.28條至第5.33條及企業管治守則條文第D.3.3及D.3.7條訂明其職權範圍(「**審核委員會**」)。審核委員會由三名獨立非執行董事組成，即徐永得先生(主席)、周國輝博士及王亞純女士。

審核委員會的主要職責包括協助董事會審閱財務資料和申報程序、風險管理和內部監控系統、內部審核職能的有效性、審核範圍和委任外聘核數師，以及讓本公司僱員可對有關本公司財務申報、內部監控或其他事宜的潛在不當行為提出關注的安排。

本報告中的財務信息尚未經過本公司審計師審閱或審核，但審核委員會成員已審閱於報告期間集團未經審核簡明綜合財務業績，及認為該等報表的編製符合適用的會計準則、GEM上市規則的規定及其他適用的法律規定，並已作出充分披露。

On behalf of the Board

Dr. Zhou Xunyong
Co-Chairman and Executive Director

Hong Kong, 28 August 2026

代表董事會

聯席主席兼執行董事
周訓勇博士

香港，二零二六年八月二十八日

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
未經審核簡明綜合損益及其他全面收入表

For the six months ended 30 June 2026 截至二零二六年六月三十日止六個月

The Board of the Directors (the "**Board**") is pleased to announce the unaudited condensed consolidated results of the Group for the six months ended 30 June 2026 together with the unaudited comparative figures for the six months ended 30 June 2025 as follows:

董事會(「**董事會**」)欣然公佈本集團截至二零二六年六月三十日止六個月的未經審核簡明綜合業績，連同截至二零二五年六月三十日止六個月的未經審核比較數字如下：

			Six months ended 30 June 截至六月三十日止六個月	
		NOTES 附註	**2026 二零二六年 (unaudited) （未經審核）** ***RMB'000 人民幣千元***	2025 二零二五年 (unaudited) （未經審核） *RMB'000 人民幣千元*
Revenue	收入	4	**16,557**	12,329
Cost of sales	銷售成本		**(5,993)**	(3,913)
Gross profit	毛利		**10,564**	8,416
Other income	其他收入	5	**121**	231
Other losses	其他虧損	6	**(289)**	(147)
Selling and distribution expenses	銷售及分銷開支		**(4,067)**	(3,520)
Administrative expenses	行政開支		**(5,975)**	(5,174)
Research and development expenses	研發開支		**(2,288)**	(1,839)
Provision for Impairment losses on trade receivables, net	貿易應收款項減值虧損，撥備淨額		**(250)**	(381)
Reversal of impairment losses on loan and loan interest receivables and refundable consideration paid	應收貸款及貸款利息及可退回已支付對價減值虧損回撥		**–**	113
Finance costs	融資成本		**(244)**	(68)
Loss before tax	除稅前虧損	7	**(2,428)**	(2,369)
Income tax expense	所得稅開支	8	**–**	–
Loss for the period	期內虧損		**(2,428)**	(2,369)
Other comprehensive expense:	其他全面開支：			
Item that may be reclassified subsequently to profit or loss	*其後可能重新分類至損益的項目*			
Exchange difference on consolidation	綜合匯兌差額		**299**	350
Total comprehensive expense for the period	期內全面開支總額		**(2,129)**	(2,019)
			RMB cents 人民幣仙	*RMB cents 人民幣仙*
Loss per share attributable to owners of the Company Basic and diluted	本公司擁有人應佔每股虧損 基本及攤薄	9	**(0.47)**	(0.47)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
未經審核簡明綜合損益及其他全面收入表

For the six months ended 30 June 2026 截至二零二六年六月三十日止六個月

		NOTES 附註	Six months ended 30 June 截至六月三十日止六個月 2026 二零二六年 (unaudited) （未經審核） RMB'000 人民幣千元	2025 二零二五年 (unaudited) （未經審核） RMB'000 人民幣千元
Loss for the period attributable to:	以下人士應佔期內虧損：			
– Owners of the Company	– 本公司擁有人		**(2,347)**	(2,369)
– Non-controlling interests	– 非控股權益		**(81)**	–
			(2,428)	(2,369)
Total comprehensive expense for the period attributable to:	以下人士應佔期內全面開支總額：			
– Owners of the Company	– 本公司擁有人		**(2,048)**	(2,019)
– Non-controlling interests	– 非控股權益		**(81)**	–
			(2,129)	(2,019)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
未經審核簡明綜合財務狀況表

At 30 June 2026 於二零二六年六月三十日

		NOTES 附註	30 June 2026 二零二六年 六月三十日 (unaudited) （未經審核） *RMB'000* *人民幣千元*	31 December 2025 二零二五年 十二月三十一日 (audited) （經審核） *RMB'000* *人民幣千元*
Non-current assets	**非流動資產**			
Property, plant and equipment	物業、廠房及設備	11	**6,722**	7,223
Right-of-use assets	使用權資產	12	**2,272**	1,343
Intangible assets	無形資產	13	**509**	781
Interest in associate	於聯營公司之權益		**–**	–
			9,503	9,347
Current assets	**流動資產**			
Inventories	存貨		**3,631**	3,241
Trade and bills receivables	貿易應收款項及應收票據	14	**11,932**	9,807
Other receivables, deposits and prepayments	其他應收款項、按金及預付款項		**1,745**	2,146
Tax recoverable	可收回稅項		**169**	128
Bank deposit with maturity over three months	存款日起三個月以上到期之銀行定期存款		**5,000**	5,000
Bank balances and cash	銀行結餘及現金		**34,242**	36,940
			56,719	57,262
Current liabilities	**流動負債**			
Trade payables	貿易應付款項	15	**1,039**	645
Other payables and accrued charges	其他應付款項及應計費用		**7,346**	8,710
Contract liabilities	合約負債		**792**	878
Lease liabilities	租賃負債		**1,575**	654
Amount due to a controlling shareholder	應付一名控股股東款項	16	**255**	255
Interest-bearing borrowing from a controlling shareholder	自一名控股股東的計息借款	17	**1,754**	–
Interest-bearing borrowings	計息貸款	18	**3,604**	3,604
Deferred income – government grants	遞延收入－政府補助		**–**	8
			16,365	14,754
NET CURRENT ASSETS	**流動資產淨值**		**40,354**	42,508
TOTAL ASSETS LESS CURRENT LIABILITIES	**資產總值減流動負債**		**49,857**	51,855

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
未經審核簡明綜合財務狀況表

At 30 June 2026 於二零二六年六月三十日

		NOTES 附註	30 June 2026 二零二六年六月三十日 (unaudited) （未經審核） RMB'000 人民幣千元	31 December 2025 二零二五年十二月三十一日 (audited) （經審核） RMB'000 人民幣千元
Non-current liabilities	**非流動負債**			
Lease liabilities	租賃負債		**730**	699
NET ASSETS	**資產淨值**		**49,127**	51,156
Capital and reserves	**資本及儲備**			
Share capital	股本	19	**4,568**	4,568
Reserves	儲備		**44,515**	46,563
Equity attributable to owners of the Company	本公司擁有人應佔權益		**49,083**	51,131
Non-controlling interests	非控股權益		**44**	25
TOTAL EQUITY	**權益總額**		**49,127**	51,156

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
未經審核簡明綜合權益變動表

For the six months ended 30 June 2026 截至二零二六年六月三十日止六個月

		Attributable to owners of the Company 本公司擁有人應佔									
		Share capital 股本 RMB'000 人民幣千元	Share premium 股份溢價 RMB'000 人民幣千元	Capital reserve 資本儲備 RMB'000 人民幣千元	Statutory reserve 法定儲備 RMB'000 人民幣千元	Translation reserve 匯兑儲備 RMB'000 人民幣千元	Share option reserve 購股權儲備 RMB'000 人民幣千元	Accumulated loss 累計虧損 RMB'000 人民幣千元	Sub-total 小計 RMB'000 人民幣千元	Non-controlling interests 非控股權益 RMB'000 人民幣千元	Total equity 權益總額 RMB'000 人民幣千元
At 1 January 2026 (audited)	於二零二六年一月一日（經審核）	4,568	60,102	1,943	2,665	(368)	–	(17,779)	46,563	25	51,156
Loss for the period	期內虧損	–	–	–	–	–	–	(2,347)	(2,347)	(81)	(2,428)
Other comprehensive Income:	**其他全面收益：**										
Item that may be reclassified subsequently to profit or loss	*其後可能重分類至損益的項目*										
Exchange difference on consolidation	綜合匯兑差額	–	–	–	–	299	–	–	299	–	299
Total comprehensive expense for the period	**期內全面開支總額**	–	–	–	–	299	–	(2,347)	(2,048)	(81)	(2,129)
Changes in ownership interests	**擁有權益變動**										
Non-controlling interest arising from capital contribution of subsidiaries	注資附屬公司產生之非控股權益	–	–	–	–	–	–	–	–	100	100
At 30 June 2026 (unaudited)	於二零二六年六月三十日（未經審核）	4,568	60,102	1,943	2,665	(69)	–	(20,126)	44,515	44	49,127
At 1 January 2025 (audited)	於二零二五年一月一日（經審核）	4,432	57,000	1,943	2,665	(753)	1,995	(13,234)	49,616	–	54,048
Loss for the period	期內虧損	–	–	–	–	–	–	(2,369)	(2,369)	–	(2,369)
Other comprehensive Income:	**其他全面收益：**										
Item that may be reclassified subsequently to profit or loss	*其後可能重分類至損益的項目*										
Exchange difference on consolidation	綜合匯兑差額	–	–	–	–	350	–	–	350	–	350
Total comprehensive expense for the period	**期內全面開支總額**	–	–	–	–	350	–	(2,369)	(2,019)	–	(2,019)
Changes in ownership interests	**擁有權益變動**										
Non-controlling interests arising from acquisition of subsidiary	收購一間附屬公司所產生的非控股權益	–	–	–	–	–	–	–	–	32	32
At 30 June 2025 (unaudited)	於二零二五年六月三十日（未經審核）	4,432	57,000	1,943	2,665	(403)	1,995	(15,603)	47,597	32	52,061

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
未經審核簡明綜合現金流量表

For the six months ended 30 June 2026 截至二零二六年六月三十日止六個月

		Six months ended 30 June 截至六月三十日止六個月	
		2026 **二零二六年** **(unaudited)** **(未經審核)** ***RMB'000*** ***人民幣千元***	2025 二零二五年 (unaudited) (未經審核) *RMB'000* *人民幣千元*
Net cash used in operating activities	經營活動所用現金淨額	**(4,795)**	(1,480)
Net cash (used in)/from investing activities	投資活動(所用)/所得現金淨額	**(198)**	4,785
Net cash from financing activities	融資活動所得現金淨額	**1,996**	1,575
Net (decrease)/increase in cash and cash equivalents	現金及現金等價物減少/增加淨額	**(2,997)**	4,880
Cash and cash equivalents at beginning of the period	年初之現金及現金等價物	**36,940**	31,495
Effect on exchange rate change	匯率變動的影響	**299**	350
Cash and cash equivalents at end of the period, represented by bank balances and cash	年末之現金及現金等價物,指銀行結餘及現金	**34,242**	36,725

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
未經審核簡明綜合財務報表附註

For the six months ended 30 June 2026 截至二零二六年六月三十日止六個月

1. GENERAL

Joyzyme Group Limited (formerly known as Huakang Biomedical Holdings Company Limited) was incorporated in the Cayman Islands as an exempted company under the laws of the Cayman Islands with limited liability on 3 August 2017 and its shares are listed on the GEM of The Stock Exchange of Hong Kong Limited on 13 December 2018. The addresses of the registered office and principal place of business of the Company are set out in the section headed "Corporate Information" to this Report.

The Group is principally engaged in research and development, manufacturing, marketing and sale of biological reagents and auxiliary reproductive supplies and equipment and healthcare products and supplements in the PRC.

The consolidated financial statements are presented in RMB, which is the same as the functional currency of the Company and rounded to the nearest thousand unless otherwise stated.

1. 一般資料

愉悅集團有限公司(前稱華康生物醫學控股有限公司)於二零一七年八月三日根據開曼群島法律於開曼群島註冊成立為一間獲豁免有限公司，其股份於二零一八年十二月十三日在香港聯合交易所有限公司GEM上市。本公司之註冊辦事處及主要營業地點地址載於本報告「公司資料」一節。

本集團主要於中國從事生物製劑及輔助生育用品和設備以及健康產品及保健品的研發、生產、營銷及銷售。

綜合財務報表以人民幣呈例，與本公司之功能貨幣相同，且除另有註明外，均四捨五入至最接近之千位數。

2. BASIS OF PRESENTATION

The unaudited condensed consolidated financial statements have been prepared in accordance with Hong Kong Financial Reporting Standards ("**HKFRSs**") issued by the Hong Kong Institute of Certified Public Accountants (the "**HKICPA**"), which collective term includes all applicable individual HKFRSs, Hong Kong Accounting Standards ("**HKASs**") and Interpretations issued by the HKICPA and the disclosure requirements of the Hong Kong Companies Ordinance. The unaudited condensed consolidated financial statements also comply with the applicable disclosure requirements of the Rules Governing the Listing of Securities on GEM of the Stock Exchange.

The accounting policies adopted in the preparation of the unaudited condensed consolidated financial statement are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended 31 December 2025, except for the adoption of the new and revised HKFRSs issued by the HKICPA that are adopted for the first time for the Group financial period beginning on 1 January 2026.

The adoption of the new and revised HKFRSs has had no significant effect on the unaudited condensed consolidated financial statements and there have been no significant changes to the accounting policies applied in the unaudited condensed consolidated financial statements.

The unaudited condensed consolidated financial statements have been prepared under the historical cost basis.

The unaudited condensed consolidated financial statements have not been audited by the Company's auditor, but have been reviewed by the Audit Committee.

2. 呈列基準

未經審核簡明綜合財務報表乃根據香港會計師公會(「**香港會計師公會**」)頒佈之所有適用個別香港財務報告準則(「**香港財務報告準則**」)、香港會計準則(「**香港會計準則**」)及詮釋(下文統稱為「**香港財務報告準則**」)以及香港公司條例的披露規定而編製。未經審核簡明綜合財務報表亦遵守聯交所GEM證券上市規則之適用披露規定。

編製未經審核簡明綜合財務報表所採納的會計政策與編製本集團截至二零二五年十二月三十一日止年度的年度綜合財務報表所應用者一致，惟於本集團自二零二六年一月一日開始之財政期間首次採用由香港會計師公會頒佈的新訂及經修訂香港財務報告準則除外。

採納新訂及經修訂香港財務報告準則對本未經審核簡明綜合財務報表並無重大財務影響。且本未經審核簡明綜合財務報表所應用之會計政策並無重大變動。

未經審核簡明綜合財務報表乃根據歷史成本基準編製。

未經審核簡明綜合財務報表尚未由本公司核數師審核，但已由審核委員會審閱。

3. USE OF JUDGEMENTS AND ESTIMATES

In preparing this unaudited condensed consolidated interim financial statements, the significant judgements made by the management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to 2025 annual financial statements.

3. 採用判斷及估計

於編製本未經審核簡明綜合中期財務報表過程中，管理層於應用本集團會計政策時作出的重大判斷及估計不確定因素的主要來源與二零二五年年度財務報表所應用者相同。

4. REVENUE AND SEGMENT INFORMATION

The Group's operating activities are attributable to research and development, manufacturing and sales of (i) biological reagents and auxiliary reproductive supplies and equipment and (ii) healthcare products and supplements.

The following is an analysis of the Group's revenue:

(a) Disaggregation of revenue from contracts with customers

4. 收益及分部資料

本集團的經營活動歸屬於研發、生產及銷售(i)生物製劑及輔助生育用品和設備及(ii)健康產品及保健品。

以下為對本集團收益之分析：

(a) 客戶合約收益分類

		Six months ended 30 June 截至六月三十日止六個月	
		2026 **二零二六年** **(unaudited)** **（未經審核）** ***RMB'000*** ***人民幣千元***	2025 二零二五年 (unaudited) （未經審核） *RMB'000* *人民幣千元*
Sales of biological reagents	銷售生物製劑		
Male fertility IVD reagents	男性不育體外診斷試劑	**10,371**	9,933
Parasite antibody detection reagents	寄生蟲系列檢測試劑	**1,403**	1,460
Epstein-Barr Virus antibody detection reagents	EB病毒檢測試劑	**179**	231
Sales of auxiliary reproductive supplies and equipment	銷售輔助生育用品和設備	**1,036**	705
Sales of healthcare products and supplements	銷售健康產品及保健品	**3,568**	–
Total	總計	**16,557**	12,329

Information reported to the executive directors of the Company, being identified as the chief operating decision makers (the "**CODM**"), for the purposes of resource allocation and assessment of segment performance focuses on types of goods or services delivered or provided. No operating segments identified by the CODM have been aggregated in arriving at the reportable segments of the Group.

就資源分配及分部業績評估而向本公司執行董事(即主要營運決策人(「**主要營運決策人**」))報告的資料著重於所交付或提供的商品或服務的類型。釐定本集團可呈報分部時，概無將主要營運決策人所識別的經營分部合併計算。

Based on the Group's internal information reporting purpose, the directors of the Company have determined that there are two reportable operating segments which are set out below:

根據本集團內部資料呈報目的，本公司董事已釐定存在兩個可呈報經營分部，載列如下：

(1) Biological reagents and auxiliary reproductive supplies and equipment; and

(2) Healthcare products and supplements

(1) 生物製劑及輔助生育用品和設備；及

(2) 健康產品及保健品

For the purpose of assessing segment performance and allocating resources between segments, the CODM makes decisions according to the operating results of each segment.

就評估分類表現及在分類間分配資源而言，主要營運決策人根據各分部的經營業績作出決策。

Segment results, which are the measures reported to the CODM for the purposes of resources allocation and assessment of segment performance, represent the profit earned or loss incurred by each segment without allocation of certain other gains and losses, administrative expenses, finance costs incurred by head office, income tax expense and share result of an associate.

分部業績為呈報予主要營運決策人以供資源分配及評估分部表現的計量基準，其指各分部賺取的溢利或產生的虧損，當中並無分配若干其他收益及虧損、行政開支、總辦公室產生的融資成本、所得稅開支及分佔聯營公司業績。

(b) Segment revenue and results

(b) 分部收益及業績

		Six months ended 30 June 截至六月三十日止六個月					
		Biological reagents and auxiliary reproductive supplies and equipment 生物製劑及輔助生育用品和設備		Healthcare products and supplements 健康產品及保健品		Total 總計	
		2026 二零二六年 (Unaudited) (未經審核) *RMB'000 人民幣千元*	2025 二零二五年 (Unaudited) (未經審核) *RMB'000 人民幣千元*	**2026 二零二六年 (Unaudited) (未經審核) *RMB'000 人民幣千元***	2025 二零二五年 (Unaudited) (未經審核) *RMB'000 人民幣千元*	**2026 二零二六年 (Unaudited) (未經審核) *RMB'000 人民幣千元***	2025 二零二五年 (Unaudited) (未經審核) *RMB'000 人民幣千元*
Segment revenue	分部收益	**12,989**	12,329	**3,568**	–	**16,557**	12,329
Segment results	分部業績	**1,567**	588	**(993)**	(545)	**574**	43
Unallocated head office and corporate income and expenses	**未分配總辦公室及公司收入及開支**						
– Other losses	－其他虧損					**(197)**	(134)
– Administrative expenses	－行政開支					**(2,617)**	(2,345)
– Reversal of impairment losses on loan and loan interest receivables and refundable consideration paid	－應收貸款及貸款利息及可退回已支付對價減值虧損回撥					**–**	113
– Finance costs	－融資成本					**(188)**	(46)
Loss before taxation	除稅前虧損					**(2,428)**	(2,369)
Income tax expenses	所得稅開支					**–**	–
Loss for the period	期內虧損					**(2,428)**	(2,369)

(c) Geographical information

The following table sets out information about the geographical location of the Group's revenue from external customers which are based on the location of goods delivered.

(c) 地域資料

下表載列按貨品交付的地區劃分之本集團外部客戶收益之地域資料。

		Six months ended 30 June 截至六月三十日止六個月 2026 二零二六年 *RMB'000* *人民幣千元*	2025 二零二五年 *RMB'000* *人民幣千元*
The PRC	中國	**16,557**	12,329

(d) Information about major customers

Details of the customers (including entities under common control) individually accounting for 10% or more of the Group's total revenue are as follows:

(d) 有關主要客戶的資料

單獨佔本集團總收益10%或以上的客戶(包括受共同控制實體)的詳情如下:

		Six months ended 30 June 截至六月三十日止六個月 2026 二零二六年 *RMB'000* *人民幣千元*	2025 二零二五年 *RMB'000* *人民幣千元*
Healthcare products and supplements	健康產品及保健品		
Customer A	客戶A	**2,274**	(Note) (附註)

Note: The customer contributed less than 10% of the total revenue of the Group for the six months ended 30 June 2025.

附註: 截至二零二五年六月三十止六個月，該客戶貢獻的收入佔本集團總收入不足10%。

5. OTHER INCOME 5. 其他收入

		Six months ended 30 June 截至六月三十日止六個月	
		2026 二零二六年 (unaudited) （未經審核） *RMB'000 人民幣千元*	2025 二零二五年 (unaudited) （未經審核） *RMB'000 人民幣千元*
Bank interest income	銀行利息收入	**100**	154
Government grants	政府補助	**21**	48
Loan interest income	貸款利息收入	**–**	29
		121	231

6. OTHER LOSSES 6. 其他虧損

		Six months ended 30 June 截至六月三十日止六個月	
		2026 二零二六年 (unaudited) （未經審核） *RMB'000 人民幣千元*	2025 二零二五年 (unaudited) （未經審核） *RMB'000 人民幣千元*
Foreign exchange losses, net	匯兑虧損，淨額	**(289)**	(147)

7. LOSS BEFORE TAX

7. 除稅前虧損

		Six months ended 30 June 截至六月三十日止六個月	
		2026 二零二六年 (unaudited) （未經審核） *RMB'000 人民幣千元*	2025 二零二五年 (unaudited) （未經審核） *RMB'000 人民幣千元*
Finance costs	**融資成本**		
Finance charges on lease liabilities	租賃負債的財務費用	**71**	23
Interest on unsecured borrowings	無抵押貸款利息	**158**	45
Interest on amount due to a controlling shareholder	應付一名控股股東款項利息	**15**	–
		244	68
Staff costs, including directors' remuneration	**員工成本，包括董事薪酬**		
Directors' emoluments	董事薪酬	**1,389**	1,286
Other staff costs:	其他員工成本：		
Salaries, bonus and other benefits	薪金、花紅及其他福利	**5,720**	4,690
Contributions to defined contribution plans	定額供款計劃供款	**1,347**	1,179
		8,456	7,155
Other items	**其他項目**		
Auditor's remuneration	核數師酬金	**351**	374
Amortisation of intangible assets (included in cost of sales)	無形資產攤銷（包含在銷售成本）	**272**	332
Cost of inventories	存貨成本	**5,993**	3,913
Depreciation of property, plant and equipment	物業、廠房及設備折舊	**798**	738
Depreciation of right-of-use assets	使用權資產折舊	**842**	567
Other rental and related expenses – Short term lease	其他租賃及有關開支－短期租賃	**–**	137
Loss on disposal of property, plant and equipment	出售物業、廠房及設備虧損	**–**	81

8. INCOME TAX EXPENSE 8. 所得税開支

		Six months ended 30 June 截至六月三十日止六個月	
		2026 **二零二六年** **(unaudited)** **（未經審核）** ***RMB'000*** ***人民幣千元***	2025 二零二五年 (unaudited) （未經審核） *RMB'000* *人民幣千元*
Current tax	**即期税項**		
PRC Enterprise Income Tax – Current year	中國企業所得税 一本年度	**–**	–

The Company and the subsidiaries incorporated in the BVI are tax-exempted. Entity established in the PRC is subject to PRC Enterprise Income Tax at a statutory rate of 25%. Since the Group's PRC subsidiary, Shenzhen Huakang is recognised as "New and High Technology Enterprise" and therefore is entitled to a concessional tax rate of 15%. The entitlement of this tax benefit is subject to renewal by respective tax bureau in the PRC every three years. The latest approval for Shenzhen Huakang enjoying this tax benefit was obtained in 15 November 2023 for the three years ending 14 November 2026.

本公司及於英屬處女群島註冊成立的附屬公司均免稅。於中國成立之實體須按中國企業所得稅法定稅率25%繳納稅項。由於本集團的中國附屬公司深圳華康獲評為「高新技術企業」，因此可享有15%的優惠稅率。該項稅務優惠資格須每三年獲相關中國稅務局重續。深圳華康最近獲此稅務優惠審批之時間為二零二三年十一月十五日，有效期為截至二零二六年十一月十四日止三年。

Hong Kong Profits Tax has not been provided as the Group had no assessable profit arising from Hong Kong for the six months ended 30 June 2026 and 2025.

由於本集團於截至二零二六年及二零二五年六月三十日止六個月並無在香港產生應課稅溢利，故並無就香港利得稅作出撥備。

No provision for deferred taxation has been made in the unaudited condensed consolidated financial statements as there were no significant temporary differences arising during the six months ended 30 June 2026 and 2025 or at the end of each reporting period.

由於截至二零二六年及二零二五年六月三十日止六個月或各報告期末並無重大暫時性差異，因此未經審核簡明綜合財務報表並無計提遞延稅項撥備。

9. LOSS PER SHARE ATTRIBUTABLE TO OWNERS OF THE COMPANY

9. 本公司擁有人應佔每股虧損

The calculation of the basic loss per share attributable to the owners of the Company is based on the following data:

本公司擁有人應佔每股基本虧損的計算乃基於以下數據：

		Six months ended 30 June 截至六月三十日止六個月	
		2026 二零二六年 (unaudited) （未經審核） *RMB'000 人民幣千元*	2025 二零二五年 (unaudited) （未經審核） *RMB'000 人民幣千元*
Loss:	**虧損：**		
Loss for the period attributable to the owners of the Company for the purpose of basic loss per share	計算每股基本虧損所用本公司擁有人應佔期內虧損	**(2,428)**	(2,369)
		'000 千股	*'000 千股*
Number of shares:	**股份數目：**		
Weighted average number of ordinary shares of the Company in issue for the purpose of basic loss per share	計算每股基本虧損所用本公司已發行普通股加權平均數	**515,472**	500,472

No diluted loss per share for the six months ended 30 June 2026 as there were no potential ordinary shares in issue for the six months ended 30 June 2026.

由於二零二六年六月三十日止六個月無潛在已發行普通股，故於二零二六年六月三十日止六個月並無每股攤薄虧損。

Diluted loss per share is the same as basic loss per share as the effect of potential ordinary shares is anti-dilutive during the six months ended 30 June 2025.

截至二零二五年六月三十日止六個月，由於普通股具有潛在反攤薄效應，故每股攤薄虧損與每股基本虧損相同。

10. DIVIDEND

No dividend was paid or declared by the Company during the six months ended 30 June 2026 and 2025, nor has any dividend been proposed since the end of the Reporting Period.

10. 股息

截至二零二六年及二零二五年六月三十日止六個月，本公司概無派付或宣派任何股息，及自報告期末亦無建議派付任何股息。

11. PROPERTY, PLANT AND EQUIPMENT

During the six months ended 30 June 2026 the Group acquired property, plants and equipment of approximately RMB298,000 (six months ended 30 June 2025: approximately RMB404,000).

11. 物業、廠房及設備

於截至二零二六年六月三十日止六個月，本集團購買物業、廠房及設備約人民幣298,000（截至二零二五年六月三十日止六個月：約人民幣404,000）。

12. RIGHT-OF-USE ASSETS

12. 使用權資產

		Factories and office premises 工廠及辦公室物業 *RMB'000* *人民幣千元*
Reconciliation of carrying amount	**賬面值對賬**	
At 31 December 2025 (audited)	於二零二五年十二月三十一日（經審核）	1,343
Additions	添置	2,315
Disposals	出售	(544)
Depreciation	折舊	(842)
At 30 June 2026 (unaudited)	於二零二六年六月三十日（未經審核）	2,272
At 30 June 2026 (unaudited)	於二零二六年六月三十日（未經審核）	
Cost	成本	**3,095**
Accumulated depreciation	累計折舊	**(823)**
		2,272

Certain leases impose a restriction that, unless the approval is obtained from the lessor, the right-of-use asset can only be used by the Group and the Group is prohibited from selling or pledging the underlying assets.

若干租賃實施一項限制，除非獲得出租人批准，否則使用權資產僅限由本集團使用，並且禁止本集團出售或抵押相關資產。

13. INTANGIBLE ASSETS 13. 無形資產

		Development costs 發展成本 *RMB'000 人民幣千元*
COST	成本	
At 31 December 2025 (audited)	於二零二五年十二月三十一日(經審核)	5,203
At 30 June 2026 (unaudited)	於二零二六年六月三十日(未經審核)	5,203
AMORTISATION	攤銷	
At 31 December 2025 (audited)	於二零二五年十二月三十一日(經審核)	4,422
Provided for the period	期內撥備	272
At 30 June 2026 (unaudited)	於二零二六年六月三十日(未經審核)	4,694
CARRYING VALUES	賬面值	
At 30 June 2026 (unaudited)	於二零二六年六月三十日(未經審核)	509
At 31 December 2025 (audited)	於二零二五年十二月三十一日(經審核)	781

Development costs are internally generated and has finite useful lives and amortised on a straight-line basis over 5 years.

發展成本乃於內部產生，具有限可用年限，並於5年內按直線法攤銷。

14. TRADE AND BILLS RECEIVABLES

14. 貿易應收款項及應收票據

		30 June 2026 二零二六年 六月三十日 (unaudited) （未經審核） *RMB'000* *人民幣千元*	31 December 2025 二零二五年 十二月三十一日 (audited) （經審核） *RMB'000* *人民幣千元*
Trade receivables from third parties	應收第三方之貿易應收款項	**18,051**	15,920
Bills receivables	應收票據	**161**	6
		18,212	15,926
Less: allowance for credit losses	減：信貸虧損撥備	**(6,280)**	(6,119)
Total	總計	**11,932**	9,807

For certain long-term customers, the Group will deliver the goods without requesting deposits and allow a credit period from 30 to 180 days (31 December 2025: 30 to 180 days) to these customers and there is no credit period granted to other customers. The Group will also request deposits from other customers before the goods are delivered and the amount of deposits requested varies amongst different contracts. The following is an aged analysis of trade receivables (net of allowance for credit losses) presented based on the dates of delivery of goods.

就若干長期客戶而言，本集團將於不要求按金的情況下向該等客戶交付貨品，且授予該等客戶30至180天（二零二五年十二月三十一日：30至180天）的信貸期，而並無向其他客戶授出信貸期。本集團亦將要求於貨品交付前向其他客戶收取按金，而所要求按金的金額因不同合約而有所區別。下列為基於貨品交付日期呈列的貿易應收款項（扣除信貸虧損備抵）的賬齡分析。

		30 June 2026 二零二六年 六月三十日 (unaudited) （未經審核） *RMB'000* *人民幣千元*	31 December 2025 二零二五年 十二月三十一日 (audited) （經審核） *RMB'000* *人民幣千元*
0–30 days	0至30天	**1,963**	1,462
31–90 days	31至90天	**3,693**	2,219
91–180 days	91至180天	**2,742**	2,937
Over 181 days	超過181天	**3,534**	3,189
		11,932	9,807

15. TRADE PAYABLES

In general, the Group will make advance payment to suppliers before the materials are received. Some of the suppliers may deliver the materials to the Group without requesting advance payment and a credit period ranged from 30 to 90 days (31 December 2024: 30 to 90 days) is granted by these suppliers. The following is an aging analysis of trade payables presented based on the invoice date:

15. 貿易應付款項

通常，本集團會在取得材料前向供應商預付款項。部份供應商可在無需預付款的情況下將材料交付予本集團，該等供應商已授出介乎30天至90天(二零二四年十二月三十一日：30天至90天)之信貸期。基於發票日期的貿易應付款項的賬齡分析如下：

		30 June 2026 二零二六年 六月三十日 (unaudited) （未經審核） *RMB'000* *人民幣千元*	31 December 2025 二零二五年 十二月三十一日 (audited) （經審核） *RMB'000* *人民幣千元*
0–30 days	0至30天	357	57
31–90 days	31至90天	177	–
Over 90 days	超過90天	505	588
		1,039	645

16. AMOUNT DUE TO A CONTROLLING SHAREHOLDER

The amount due is unsecured, interest-free and repayable on demand.

16. 應付一名控股股東款項

有關應付款項為無抵押、免息及須按要求償還。

17. INTEREST-BEARING BORROWING FROM A CONTROLLING SHAREHOLDER

The amount due is unsecured, repayable on demand and is charged at a fixed interest rate of 3% per annum.

17. 自一名控股股東的計息借款

有關借款項為無抵押、須按要求償還及按固定年利率3%計息。

18. INTEREST-BEARING BORROWINGS

Unsecured borrowings represent term loan agreements entered with a licensed money lender in Hong Kong of approximately RMB3,604,000 (equivalents to HK$4,000,000) as at 30 June 2026, which is charged at a fixed interest rate of 9% per annum. The term loans are unsecured and repayable within 12 months after the drawdown date. The maturity date of the term loans was subsequently extended further 12 months.

18. 計息借款

於二零二六年六月三十日，無抵押貸款指與香港持牌放債人訂立的有期貸款協議，金額約為人民幣3,604,000元(相當於4,000,000港元)，按固定年利率9%計息。該等有期貸款為無抵押及須於提款日期後12個月內償還。定期貸款的到期日其後進一步延後12個月。

19. SHARE CAPITAL 19. 股本

		Number of share 股份數目	*HK$ 港元*	Equivalent to 相當於 *RMB'000 人民幣千元*
Authorised: At 31 December 2025 (audited) and 30 June 2026 (unaudited)	**法定：** 於二零二五年十二月三十一日（經審核）及二零二六年六月三十日（未經審核）	1,000,000,000	10,000,000	8,851
Issued and fully paid ordinary shares at HK$0.01 per share: At 31 December 2025 (audited)	**每股0.01港元之已發行及繳足普通股：** 於二零二五年十二月三十一日（經審核）	515,472,000	5,154,720	4,568
At 30 June 2026 (unaudited)	於二零二六年六月三十日（未經審核）	515,472,000	5,154,720	4,568

20. RELATED PARTY TRANSACTIONS 20. 關連方交易

(a) Related party transactions (a) 關連方交易

Save as disclosed elsewhere in the unaudited condensed consolidated financial statements, the Group had entered into following transactions with its related party during the six months ended 30 June 2026 and 2025:

除於未經審核簡明綜合財務報表其他地方之披露外，截至二零二六年及二零二五年六月三十日止六個月，本集團與其關連方訂立以下交易：

		Six months ended 30 June 截至六月三十日止六個月	
		2026 二零二六年 (unaudited) （未經審核） ***RMB'000 人民幣千元***	2025 二零二五年 (unaudited) （未經審核） *RMB'000 人民幣千元*
Lease and utilities expenses paid to Shenzhen Junxuan Biological Technology Co., Ltd* ("**Shenzhen Junxuan**") (Note 1)	已付深圳君軒生物技術有限公司（「**深圳君軒**」）之租金及公共開支（附註1）	**–**	615
Interest expenses payable to a Controlling Shareholder	應付控股股東利息	**15**	–

* *The English name is for identification purpose*

Note:

1. Shenzhen Junxuan is a related company controlled by Mr. Zhang Shuguang, an executive director of the Company who resigned on 29 August 2025.

2. A controlling shareholder is Dr. Zhou Xunyong, an executive director and co-chairman of the Company.

附註：

1. 深圳君軒為本公司執行董事張曙光先生的關連公司其已於二零二五年八月二十九日辭任。

2. 控股股東為本公司執行董事及聯席主席周訓勇博士。

(b) Compensation of key management personnel

The emoluments of directors as key management personnel of the Group during the six months ended 30 June 2026 and 2025 were as follows:

(b) 主要管理人員薪酬

董事（作為本集團主要管理人員）截至二零二六年及二零二五年六月三十日止六個月之薪酬如下：

		Six months ended 30 June 截至六月三十日止六個月	
		2026 二零二六年 (unaudited) （未經審核） *RMB'000* *人民幣千元*	2025 二零二五年 (unaudited) （未經審核） *RMB'000* *人民幣千元*
Salaries, bonuses and other benefits	薪金、花紅及其他福利	**1,281**	1,167
Contributions to defined contribution plans	界定供款計劃供款	**108**	119
		1,389	1,286